Clinical Trials
35 trialsR-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
International Extranodal Lymphoma Study Group (IELSG)
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
PLRG8
Polish Lymphoma Research Group
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
BrUOG-377
Brown University
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
University of Texas Southwestern Medical Center
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
IVAM
Asan Medical Center
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Tandem Auto-Allo Transplant for Lymphoma
Massachusetts General Hospital
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Alliance for Clinical Trials in Oncology
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Children's Oncology Group
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Northside Hospital, Inc.
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
SWOG Cancer Research Network
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
University of California, San Francisco
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Northside Hospital, Inc.
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
SWOG Cancer Research Network
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
Fred Hutchinson Cancer Center